Lundbeck's Bocunebart Meets Primary Endpoint in Phase IIb Migraine Prevention Trial, Opening a New Pathway Beyond CGRP

Denmark-based H. Lundbeck A/S announced positive topline results from the intravenous dosing arm of its Phase IIb PROCEED trial evaluating bocunebart (Lu AG09222), an anti-PACAP monoclonal antibody, for bocunebart migraine prevention in patients who had failed prior preventive therapies. The trial met its primary endpoint, demonstrating a statistically significant reduction versus placebo in monthly migraine days over a 12-week treatment period. If the finding holds in later-stage testing, Lundbeck bocunebart would represent the first approved therapy targeting the pituitary adenylate cyclase-activating polypeptide pathway, a mechanism distinct from the anti-CGRP antibodies that have dominated migraine prevention drug development over the past decade.

Trial Specifics: Lu AG09222 Phase IIb Results From the PROCEED Study

The PROCEED trial is an adaptive Phase IIb dose-finding study designed to evaluate multiple doses and two routes of administration — intravenous and subcutaneous — of bocunebart in adults diagnosed with migraine according to the International Classification of Headache Disorders, Third Edition. The current readout pertains only to the IV portion of the study. A total of 431 patients across 14 countries were randomized to receive bocunebart or placebo administered once monthly for three months. The enrolled population was required to have experienced between one and four preventive treatment failures in the preceding 10 years, selecting for patients with a history of inadequate response to existing therapies.

The primary efficacy endpoint was the mean change from baseline in the number of monthly migraine days over weeks 1 to 12, comparing bocunebart against placebo. Lundbeck reported that this endpoint was met with statistical significance, though the company did not disclose specific numerical reductions, p-values, or confidence intervals in its topline announcement. The company said bocunebart was generally well tolerated and that no new safety signals were detected. Detailed efficacy and safety data are expected at an upcoming scientific conference and in a subsequent peer-reviewed publication. Lundbeck noted that additional analyses are planned to characterize the dose-response relationship across the IV dose levels tested.

The PROCEED trial migraine data build on the earlier HOPE Phase IIa study, which evaluated a single IV administration of bocunebart and also generated positive results. The subcutaneous arm of PROCEED was not addressed in this announcement and may be reported separately.

Based on the positive outcome, Lundbeck said it will approach regulatory authorities to discuss the results and Phase III design options. Johan Luthman, executive vice president and head of research and development at Lundbeck, said the data "underline Lundbeck's ambition to deliver the first PACAP targeting option in migraine prevention." Jessica Ailani, the coordinating investigator and a certified headache specialist in Washington, D.C., described the efficacy demonstrated in the trial as "a promising advancement in the treatment of migraine." No specific timeline for a Phase III start or regulatory filing was disclosed.

The Science Behind Bocunebart: Anti-PACAP Migraine Therapy and Why It Matters

Bocunebart is an investigational bocunebart PACAP monoclonal antibody engineered to bind and neutralize PACAP, a neuropeptide found in migraine-relevant neural circuits including the trigeminal ganglion and trigeminocervical complex. PACAP exists in two forms — PACAP-38 and PACAP-27 — and signals through three receptor subtypes: PAC1, VPAC1, and VPAC2. Human provocation studies have shown that intravenous PACAP-38 infusion can trigger delayed migraine-like attacks in susceptible individuals, and elevated plasma PACAP levels have been observed during migraine attacks. By targeting the ligand itself rather than a single receptor subtype, bocunebart blocks PACAP signaling across all three receptors, a pharmacological distinction that may be relevant given the failure of receptor-selective approaches in clinical testing.

Importantly, research has established that PACAP-induced migraine attacks can occur independently of CGRP signaling, suggesting the two pathways play overlapping but partly independent roles in migraine pathophysiology. This provides a biological rationale for pursuing anti-PACAP migraine therapy specifically in patients who have not responded adequately to CGRP-targeted preventives — the population enrolled in PROCEED.

Bocunebart is not approved by the US FDA or any other regulatory authority. No US FDA special designations such as Fast Track, Breakthrough Therapy, or Orphan Drug status have been publicly confirmed for the molecule. The compound originated from the now-dissolved Lundbeck-AbbVie neuroscience collaboration, with Lundbeck assuming sole development and commercialization rights. Lundbeck also acquired Alder BioPharmaceuticals in 2019, which had been developing ALD1910, a separate anti-PACAP-38 antibody that appears to have been superseded by bocunebart in Lundbeck's pipeline.

Competitive Landscape: Bocunebart Migraine Prevention in Context

The anti-PACAP migraine space remains sparsely populated compared to the crowded CGRP-targeting field, where four approved monoclonal antibodies — erenumab (Aimovig, Amgen/Novartis), fremanezumab (Ajovy, Teva), galcanezumab (Emgality, Eli Lilly), and eptinezumab (Vyepti, Pfizer/Lundbeck) — are already marketed for migraine prevention. Bocunebart is the most advanced PACAP-targeting molecule in clinical development. Key competitors and related programs include:

• Amgen's AMG 301, a monoclonal antibody targeting the PAC1 receptor rather than the PACAP ligand, which completed a Phase II trial in episodic migraine but failed to meet its primary endpoint. The negative result raised questions about whether selective PAC1 receptor blockade is sufficient, while leaving open the possibility that broader ligand neutralization — as bocunebart attempts — could prove more effective by blocking signaling through all three PACAP receptor subtypes.

• Lundbeck's own ALD1910, the anti-PACAP-38 antibody acquired through the Alder BioPharmaceuticals purchase, which demonstrated preclinical activity in blocking PACAP-38-induced vasodilation but has not advanced into clinical testing as a separate program. Its development appears to have been folded into or replaced by the bocunebart program.

• Various academic groups have explored small molecule PAC1 receptor antagonists, though none have reached clinical-stage development for migraine.

The failure of AMG 301 is a notable data point for interpreting the PROCEED results. That a receptor-targeted approach did not succeed while a ligand-targeted one has now shown efficacy may reflect meaningful pharmacological differences, though cross-trial comparisons carry obvious limitations given differences in patient populations, dosing, and trial design. Whether bocunebart's ligand-blocking strategy translates into durable clinical benefit in a Phase III setting remains to be established.

For migraine patients who have cycled through available CGRP-targeted preventives without adequate relief, a therapy acting through an independent pathway would address a genuine gap in the current treatment armamentarium. Lundbeck's next steps — regulatory discussions and Phase III planning — will determine whether bocunebart can move from a positive dose-finding signal to a registrational program capable of supporting approval.

---

Spot something wrong? Report an issue with this article